Myeloproliferative Neoplasms Associated with Mutation in JAK2V617F and Tyrosine Kinase Inhibitors as Therapeutic Strategy
MPNs including a heterogeneous group of clonal or oligoclonal hamtopathies characterized by proliferation and accumulation of mature myeloid cells. JAK2 tyrosine kinase mutation is the most common molecular lesion identified in 90% of cases. JAK2 is involved in EPO signaling pathway, and mutations i...
Main Authors: | Kaveh Tari, Amir Atashi, Reza Yarahmadi, Saeid Abroun, Abbas Hajifathali, Saeid Kaviani, Masoud Soleimani |
---|---|
Format: | Article |
Language: | English |
Published: |
Mazandaran University of Medical Sciences and Health Services
2015-04-01
|
Series: | Research in Molecular Medicine |
Subjects: | |
Online Access: | http://rmm.mazums.ac.ir/browse.php?a_code=A-10-678-4&slc_lang=en&sid=1 |
Similar Items
-
Myeloproliferative disorders and its associated mutations
by: Kaveh Tari, et al.
Published: (2014-10-01) -
Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation
by: Bennemann Karla, et al.
Published: (2012-08-01) -
JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients
by: Fanti Saktini, et al.
Published: (2015-12-01) -
JAK2-positive Philadelphia-negative myeloproliferative neoplasms
by: Anjali Sharma, et al.
Published: (2011-01-01) -
Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms
by: Min Hu, et al.
Published: (2019-02-01)